Bandhan Healthcare Fund
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.
Growthvine rating: 1/5 — ranked #83 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹10.92 (as of 2026-10-01) |
|---|
| AUM | ₹319 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Viraj Kulkarni |
|---|
| Exit load | 0.5% for redemption within 30 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −8.92% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 105.6% of NIFTY Pharma's upside and — of its downside.
Market cap allocation
| Large cap | 31.4% |
|---|
| Mid cap | 33.3% |
|---|
| Small cap | 35.3% |
|---|
Concentration
| Top 5 holdings | 32.6% |
|---|
| Top 10 holdings | 51.6% |
|---|
| Total holdings | 35 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 10.5%
- Cipla Ltd. — 6.4%
- Max Healthcare Institute Limited — 5.8%
- Apollo Hospitals Enterprises Ltd. — 5.6%
- Triparty Repo TRP_010926 — 4.3%
- Divis Laboratories Ltd. — 4.3%
- Aurobindo Pharma Ltd. — 4.1%
- Lupin Ltd — 4.0%
- Shilpa Medicare Ltd. — 3.7%
- GlaxoSmithkline Pharmaceuticals Ltd. — 3.7%
Top sectors
- Pharma & Biotech — 70.0%
- Healthcare — 25.0%
- Cash — 4.0%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 11.6% | Q1 (Top) | #14 of 76 |